{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:16:08Z","timestamp":1740107768797,"version":"3.37.3"},"reference-count":4,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T00:00:00Z","timestamp":1612569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T00:00:00Z","timestamp":1612569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"DOI":"10.1007\/s10147-021-01878-z","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:15:36Z","timestamp":1612829736000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reply to comments on \u201cEfficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei\u201d"],"prefix":"10.1007","author":[{"given":"Sakura","family":"Hiraide","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keigo","family":"Komine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanobu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3023-1227","authenticated-orcid":false,"given":"Chikashi","family":"Ishioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,6]]},"reference":[{"key":"1878_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.7326\/0003-4819-156-1-201201030-00006","volume":"156","author":"OM Dekkers","year":"2012","unstructured":"Dekkers OM, Egger M, Altman DG et al (2012) Distinguishing case series from cohort studies. Ann Intern Med 156:37\u201340","journal-title":"Ann Intern Med"},{"issue":"Suppl 3","key":"1878_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.2106\/JBJS.H.01597","volume":"91","author":"DM Bryant","year":"2009","unstructured":"Bryant DM, Willits K, Hanson BP (2009) Principles of designing a cohort study in orthopaedics. J Bone Joint Surg Am 91(Suppl 3):10\u201314","journal-title":"J Bone Joint Surg Am"},{"issue":"Suppl 3","key":"1878_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2106\/JBJS.H.01573","volume":"91","author":"B Kooistra","year":"2009","unstructured":"Kooistra B, Dijkman B, Einhorn TA et al (2009) How to design a good case series. J Bone Joint Surg Am 91(Suppl 3):21\u201326","journal-title":"J Bone Joint Surg Am"},{"key":"1878_CR4","doi-asserted-by":"publisher","first-page":"W163","DOI":"10.7326\/0003-4819-147-8-200710160-00010-w1","volume":"147","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, von Elm E, Altman DG et al (2007) Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med 147:W163\u2013W194","journal-title":"Ann Intern Med"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-021-01878-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-021-01878-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-021-01878-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T14:25:15Z","timestamp":1617287115000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-021-01878-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,6]]},"references-count":4,"alternative-id":["1878"],"URL":"https:\/\/doi.org\/10.1007\/s10147-021-01878-z","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"type":"print","value":"1341-9625"},{"type":"electronic","value":"1437-7772"}],"subject":[],"published":{"date-parts":[[2021,2,6]]},"assertion":[{"value":"30 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Chikashi Ishioka received research funding from the Tokyo Cooperative Oncology Group. Chikashi Ishioka received contributions from Chugai Pharmaceutical, Asahi Kasei Pharma Corporation, Ono pharmaceutical, MSD, Pfizer, AstraZeneca, Bristol-Myers Squibb, Janssen Pharmaceutical, Taiho Pharmaceutical, Eisai Pharmaceutical, Daiichi Sankyo Company, Limited, and Takeda Pharmaceutical. Masanobu Takahashi has received research funding from Ono Pharmaceutical Company. Chikashi Ishioka is a representative of Tohoku Clinical Oncology Research and Education Society, a specified non-profit corporation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}